CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 95 enrolled
Drug / intervention
Levodopa/carbidopa/entacapone +1 moredrug
Likely dose
Levodopa/carbidopa/entacapone 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00391898
NCT00391898Phase 4Completed
CompareCT.gov

A 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With Levodopa

Novartis·interventional·Posted Oct 25, 2006·Updated Mar 15, 2011

In Brief

A Phase 4 clinical trial evaluating Levodopa/carbidopa/entacapone and Levodopa/carbidopa for Parkinson's Disease. Completed, enrolled 95 participants across 26 sites.

Detailed Summary

The study evaluated the efficacy of levodopa/carbidopa/entacapone vs levodopa/carbidopa in patients with Parkinson's disease and early wearing-off with levodopa

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesSpain
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 25, 2006
Enrollment StartOct 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.7 years ago

Interventions

Levodopa/carbidopa/entacaponedrug

Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.

Levodopa/carbidopadrug

Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.